comparemela.com

Latest Breaking News On - Aurion biotech - Page 1 : comparemela.com

ASCRS 2024: Healio s top items so far

ASCRS 2024: Healio s top items so far
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

First Canadian patient dosed in cell therapy trial for corneal edema

First Canadian patient dosed in cell therapy trial for corneal edema
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Aurion Biotech to Present Clinical Data at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Aurion Biotech to Present Clinical Data at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Aurion Biotech Announces First Canadian Subject Dosed in Phase 1 / 2 Clinical Trial

SEATTLE & CAMBRIDGE, Mass. & TOKYO, March 28, 2024 Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced that it has dosed the first Canadian subject in its Phase 1 / 2 clinical trial (ABA-1, CLARA) of AURN001, a cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction.

Scion Life Sciences Launches with Oversubscribed $310 Million Fund to Create and Build Exceptional Biotech Companies

Scion Life Sciences Launches with Oversubscribed $310 Million Fund to Create and Build Exceptional Biotech Companies
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.